Related Experiment Videos
Hepatitis C: an update
1Academic Department of Medicine, Royal Free Hospital, Hampstead London.
Insights
Hepatitis C virus (HCV) identification revolutionized diagnostics and epidemiology. While interferon shows promise, further antiviral research is needed for effective Hepatitis C treatment.
Area of Science:
- Virology
- Immunology
- Epidemiology
Background:
- Hepatitis C virus (HCV) identification marked a significant advancement, replacing the term Non-A Non-B Hepatitis.
- This discovery enabled specific antibody detection assays, facilitating sero-epidemiological studies of HCV infection.
Purpose of the Study:
- To outline the epidemiology and diagnostic approaches for Hepatitis C virus (HCV).
- To review current treatment strategies and future therapeutic directions for Hepatitis C.
Main Methods:
- Utilized molecular cloning for Hepatitis C virus identification.
- Reviewed diagnostic tests including ELISA anti-HCV, recombinant immunoblot assay, HCV-RNA by PCR, and HCV-Ag.
- Examined sero-epidemiological data on Hepatitis C antibody carriage and transmission routes.
Main Results:
- Hepatitis C antibody carriage varies globally, with highest prevalence in intravenous drug users and hemophiliacs.
- Parenteral transmission is primary; sexual, familial, and perinatal routes are less common. Approximately 40% are community-acquired.
- Over 50% of acute cases become chronic, with 20% progressing to cirrhosis and potential hepatocellular carcinoma.
Conclusions:
- Interferon therapy shows some efficacy but has a 50% relapse rate.
- Further clinical trials with interferon and antivirals like ribavirin are essential for improved Hepatitis C treatment outcomes.
Abstract:
The identification of the Hepatitis C virus using molecular cloning techniques, besides making the term Non-A Non-B Hepatitis obsolete, enables the development of specific assays for the detection of antibodies in HCV-infected individuals, thus making it possible to obtain sero-epidemiological data of the disease. The carriage of Hepatitis C antibody varies worldwide. The disease is most prevalent in intravenous drug abusers or haemophiliacs. Parenteral transmission is the most important route of transmission. Sexual, intra-familial and perinatal transmissions are uncommon. About 40% could be community-acquired (sporadic). Diagnostic tests include enzyme-linked immunosorbant (ELISA) anti-HCV assay, recombinant immunoblot assay, HCV-RNA by polymerase chain reaction and HCV-Ag. More than 50% of acute cases becomes chronic and runs a benign and indolent course. About 20% progress to cirrhosis and some of these develop hepatocellular carcinoma. Several published trials have consistently shown that treatment with interferon in some patients is useful. There is however a relapse rate of 50%. Further trials with interferon and other anti-viral agents like ribavirin are awaited for more effective treatment.